In this webinar, Mikalai Malinouski Ph.D.demonstrated how BioSymetrics uses AI in the prediction of mechanism of action (MOA), and provided a an example of how machine learning workflows can benefit both novel drug discovery and drug repositioning.

Dr. Kevin Folta discusses how the genomics era has generated tremendous data sets, yet the information they reveal is limited by the human biases that search them.  Are there ways to examine complex data sets for hidden patterns that can unearth new perspectives in biology?  This is the role of machine learning, and the patterns form the basis of artificial intelligence that then executes new tasks.  While these concepts seem difficult to fathom, Dr. Gabe Musso makes them understandable, and describes the ways they may be applied in contemporary contexts.

Anthony Iacovone, Chairman of BioSymetrics, joins host Dr. Bob Kaiser for a discussion about what biomedical artificial intelligence and machine learning are and how they can be used to improve outcomes in the areas of drug discovery, clinical diagnostics and value-based care as well as reduce healthcare costs.